WATERTOWN, Mass., May 23, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced seventeen data presentations at the American Society of Microbiology (ASM) Microbe 2016 Conference, taking place June 16-20 in Boston, MA. Presentations will include information about the company’s lead drug candidate, eravacycline, as well as data from its TP-271 program.
The details for the data presentations at ASM Microbe 2016 are as follows:
Eravacycline presentations:
Poster #264: Intravenous Eravacycline With Transition To Oral Therapy for Treatment of Complicated Urinary Tract Infections (cUTI) Including Pyelonephritis: Results From A Randomized, Double-Blind, Multicenter, Phase 3 Trial (IGNITE2)
Date and time: Monday, June 20 from 12:30 – 2:30 p.m. ET
Session info: Laboratory Diagnosis and Antimicrobial Susceptibility of UTI Pathogens
Poster #265: Intravenous Eravacycline Compared to Intravenous Levofloxacin for the Treatment of Complicated Urinary Tract Infections (cUTI): Subgroup Analysis from a Randomized, Double-Blind, Phase 3 Trial (IGNITE2)
Date and time: Monday, June 20 from 12:30 – 2:30 p.m. ET
Session info: Laboratory Diagnosis and Antimicrobial Susceptibility of UTI Pathogens
Poster #266: Risk Factors for Change in Microbiological Outcomes between the End of Therapy (EOT) and Post-Treatment (PT) Evaluations in Patients with Complicated UTI (cUTI) Treated with Eravacycline (ERV): Analysis from a Randomized, Double-Blind, Phase 3 Trial (IGNITE2)
Date and time: Monday, June 20 from 12:30 – 2:30 p.m. ET
Session info: Laboratory Diagnosis and Antimicrobial Susceptibility of UTI Pathogens
Poster #426: Evaluation of Patients with Complicated Intra-abdominal Infections (cIAI) and Concomitant Bacteremia (CB) from IGNITE1: A Phase 3 Study to Evaluate the Efficacy and Safety of Eravacycline (ERV) versus Ertapenem (ETP) in Complicated Intra-Abdominal Infections (cIAI)
Date and time: Friday, June 17 from 12:30 – 2:30 p.m. ET
Session info: Evaluation of Clinical Outcomes among Patients with Gram-negative Bloodstream and Complicated Infections
Poster #451: Patient Outcomes with Complicated Intra-Abdominal Infections (cIAI) Caused by Gram-Negative Pathogens from IGNITE1: A Phase 3 Study to Evaluate the Efficacy and Safety of Eravacycline (ERV) versus Ertapenem (ETP)
Date and time: Saturday, June 18 from 12:45 – 2:45 p.m. ET
Session info: Evaluation of Clinical Outcomes among Patients with Gram-negative Bloodstream and Complicated Infections
Poster #005: In Vitro Activity of Eravacycline and Comparators Against Enterobacteriaceae, Including Strains Resistant to Carbapenems or 3rd/4th Generation Cephalosporins in the US
Date and time: Monday, June 20 from 12:30 – 2:30 p.m. ET
Session info: Antimicrobial Susceptibility Testing of Newer and ReNewed Antimicrobial Agents
Poster #007: In Vitro Activity of Eravacycline and Comparators Against Acinetobacter baumannii, Including Carbapenem-resistant Strains, and Stenotrophomonas maltophilia Isolated from Patients in the US
Date and time: Monday, June 20 from 12:30 – 2:30 p.m. ET
Session info: Antimicrobial Susceptibility Testing of Newer and ReNewed Antimicrobial Agents
Poster #008: Eravacycline In Vitro Activity Against Clinical Isolates Obtained from Genitourinary (GU) and Gastrointestinal (GI) Sources from Patients in the US
Date and time: Monday, June 20 from 12:30 – 2:30 p.m. ET
Session info: Antimicrobial Susceptibility Testing of Newer and ReNewed Antimicrobial Agents
Poster #566: Eravacycline is Active against MDR, Cephalosporin- and Carbapenem- Resistant Enterobacteriaceae and Acinetobacter baumannii
Date and time: Monday, June 20 from 12:30 – 2:30 p.m. ET
Session info: Tetracyclines, Aminoglycosides, and Related Compounds
Poster #550: Eravacycline In Vitro Antibacterial Activity against 110 Carbapenemase-Producing Enterobacteriaceae Clinical Isolates
Date and time: Monday, June 20 from 12:30 – 2:30 p.m. ET
Session info: Tetracyclines, Aminoglycosides, and Related Compounds
Poster #568: Activity of Eravacycline and Comparators against 6,338 Pathogens Isolated from Canadian Hospitals: Canward 2014 and 2015
Date and time: Monday, June 20 from 12:30 – 2:30 p.m. ET
Session info: Tetracyclines, Aminoglycosides, and Related Compounds
Poster #511: Antibacterial Efficacy of Eravacycline (ERV) In Vivo Against Gram-positive and Gram-negative Organisms
Date and time: Monday, June 20 from 12:30 – 2:30 p.m. ET
Session info: Pharmacokinetic/Pharmacodynamic (PK/PD) of New Drugs
Oral presentation title: Eravacycline (ERV) Pharmacokinetics (PK) and Challenges in Defining Humanized Exposure In Vivo
Date, time and location: Sunday, June 19 at 8:45 a.m. ET, Meeting Room 156A
Session info: Innovations and Challenges in Pharmacokinetics/Pharmacodynamics (PK/PD)
TP-271 presentation:
Poster #536: TP-271 is Efficacious in a Francisella tularensis Cynomolgus Monkey Treatment Model
Date and time: Monday, June 20 from 12:30 – 2:30 p.m. ET
Session info: Tetracyclines, Aminoglycosides, and Related Compounds
Additional presentations:
Oral presentation title: The Impact of ramR Sequence Variations on Tigecycline Susceptibility in Klebsiella pneumoniae
Date, time and location: Monday, June 20 at 8:15 a.m. ET, Meeting Room 157A
Session info: RNA Modulation and Cellular Signals in Antimicrobial Resistance
Poster #140: Multidrug Resistance Gram-negative (MDR-GN) Organisms in the Inpatient and Outpatient Settings in the US: 2008-2015
Date and time: Monday, June 20 from 12:30 – 2:30 p.m. ET
Session info: Drugs, Bugs, Body Sites and Antibiograms
Poster #145: Multidrug-resistance Acinetobacter baumannii (MDR AB) Trends from All Sources in the Inpatient and Outpatient Setting in US Hospitals: 2008-2015
Date and time: Monday, June 20 from 12:30 – 2:30 p.m. ET
Session info: Drugs, Bugs, Body Sites and Antibiograms
ASM Microbe 2016 is the integration of two of the American Society of Microbiology’s meetings: the General Meeting and ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy).
Full abstracts can be found on the ASM Microbe website at http://www.asmmicrobe.org/.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes its late-stage antibiotic, eravacycline, as well as two additional antibiotic candidates, TP-271 and TP-6076. Please visit www.tphase.com for more company information.